Francesco Negro

List of Publications by Year
in descending order

159 papers	16,527 citations	30070 54 h-index	15732 125 g-index
175 all docs	175 docs citations	175 times ranked	15931 citing authors

#	Article	IF	Citations
1	HCV disease burden and population segments in Switzerland. Liver International, 2022, 42, 330-339.	3.9	14
2	Scaling-up hepatitis C screening and treatment in Swiss outpatient psychiatric settings: A cost-effectiveness analysis. JHEP Reports, 2022, 4, 100464.	4.9	0
3	Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. The Lancet Gastroenterology and Hepatology, 2022, 7, 724-735.	8.1	47
4	Residual risk of liver disease after hepatitis C virus eradication. Journal of Hepatology, 2021, 74, 952-963.	3.7	22
5	Real-world effectiveness and safety of glecaprevir/pibrentasvir therapy in patients with chronic hepatitis C virus infection in Switzerland. Swiss Medical Weekly, 2021, 151, w20399.	1.6	4
6	HDV Pathogenesis: Unravelling Ariadneâ€™s Thread. Viruses, 2021, 13, 778.	3.3	14
7	NAFLD and MAFLD as emerging causes of HCC: A populational study. JHEP Reports, 2021, 3, 100231.	4.9	54
8	The neverâ€ending debate about conflict of interests'. Liver International, 2021, 41, 1443-1444.	3.9	3
9	Real-World Outcomes in Historically Underserved Patients with Chronic HepatitisÂC Infection Treated with Glecaprevir/Pibrentasvir. Infectious Diseases and Therapy, 2021, 10, 2203-2222.	4.0	11
10	Hepatitis C prevalences in the psychiatric setting: Cost-effectiveness of scaling-up screening and direct-acting antiviral therapy. JHEP Reports, 2021, 3, 100279.	4.9	12
11	Endpoints and New Options for Treatment of Chronic Hepatitis D. Hepatology, 2021, 74, 3479-3485.	7.3	26
12	Hepatitis C core antigen test as an alternative for diagnosing HCV infection: mathematical model and cost-effectiveness analysis. PeerJ, 2021, 9, e11895.	2.0	2
13	Mir-21 Suppression Promotes Mouse Hepatocarcinogenesis. Cancers, 2021, 13, 4983.	3.7	17
14	Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. The Cochrane Library, 2021, 2021, .	2.8	0
15	Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a036921.	6.2	13
16	Adherence to panâ€genotypic glecaprevir/pibrentasvir and efficacy in HCVâ€infected patients: A pooled analysis of clinical trials. Liver International, 2020, 40, 778-786.	3.9	22
17	Securing sustainable funding for viral hepatitis elimination plans. Liver International, 2020, 40, 260-270.	3.9	24
18	Tolerogenic properties of liver macrophages in nonâ€alcoholic steatohepatitis. Liver International, 2020, 40, 609-621.	3.9	6

#	Article	IF	Citations
19	All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS). Open Forum Infectious Diseases, 2020, 7, ofaa308.	0.9	6
20	The MD-PhD program in Geneva: a 10-year analysis of graduate demographics and outcomes. BMC Medical Education, 2020, 20, 425.	2.4	2
21	EASL recommendations on treatment of hepatitis C: Final update of the seriesâ˜†. Journal of Hepatology, 2020, 73, 1170-1218.	3.7	671
22	Reply to: â€œCirrhotic controls in a pooled analysis of hepatitis D and hepatocellular carcinomaâ€•. Journal of Hepatology, 2020, 73, 1585-1586.	3.7	0
23	SARS-CoV-2 and liver damage: a possible pathogenetic link. Hepatobiliary Surgery and Nutrition, 2020, 9, 322-324.	1.5	7
24	Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. Journal of Hepatology, 2020, 73, 533-539.	3.7	94
25	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: AÂmeta-analysis. Journal of Hepatology, 2020, 72, 1112-1121.	3.7	62
26	Natural history of NASH and HCC. Liver International, 2020, 40, 72-76.	3.9	77
27	Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?. Swiss Medical Weekly, 2020, 150, w20249.	1.6	63
28	Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates. Clinical Gastroenterology and Hepatology, 2019, 17, 748-755.e3.	4.4	559
29	Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study. PLoS ONE, 2019, 14, e0218706.	2.5	4
30	The heavy burden of hepatitis D in Uzbekistan. Liver International, 2019, 39, 2034-2035.	3.9	0
31	Treatment with direct-acting antivirals improves peripheral insulin sensitivity in non-diabetic, lean chronic hepatitis C patients. PLoS ONE, 2019, 14, e0217751.	2.5	20
32	Interleukin-1 Receptor Antagonist Modulates Liver Inflammation and Fibrosis in Mice in a Model-Dependent Manner. International Journal of Molecular Sciences, 2019, 20, 1295.	4.1	48
33	A review on hepatitis D: From virology to new therapies. Journal of Advanced Research, 2019, 17, 3-15.	9.5	78
34	Activation of the oncogenic miRâ€21â€5p promotes HCV replication and steatosis induced by the viral core 3a protein. Liver International, 2019, 39, 1226-1236.	3.9	24
35	Very Low Hepatitis C Viral Loads in Treatment-naive Persons: Do They Compromise Hepatitis C Virus Antigen Testing?. Clinical Infectious Diseases, 2019, 70, 653-659.	5.8	13
36	IDDF2019-ABS-0212â€…Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis. , 2019, , .		0

#	Article	IF	Citations
37	Update in Drug Development for Chronic HBV/HDV Infection. Current Hepatology Reports, 2019, 18, 522-530.	0.9	0
38	Deficient Natural Killer Cell NKp30â€Mediated Function and Altered NCR3 Splice Variants in Hepatocellular Carcinoma. Hepatology, 2019, 69, 1165-1179.	7.3	48
39	Increasing hepatitis C virus screening in people who inject drugs in Switzerland using rapid antibody saliva and dried blood spot testing: A costâ€effectiveness analysis. Journal of Viral Hepatitis, 2019, 26, 236-245.	2.0	13
40	Devil hepatitis D: an orphan disease or largely underdiagnosed?. Gut, 2019, 68, 381-382.	12.1	34
41	Cost-effectiveness analysis of strategies to manage the disease burden of hepatitis C virus in Switzerland. Swiss Medical Weekly, 2019, 149, w20026.	1.6	9
42	Nonalcoholic fatty liver disease burden â€“ Switzerland 2018â€“2030. Swiss Medical Weekly, 2019, 149, w20152.	1.6	12
43	Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions. Swiss Medical Weekly, 2019, 149, w14694.	1.6	7
44	EASL Recommendations on Treatment of Hepatitis C 2018. Journal of Hepatology, 2018, 69, 461-511.	3.7	1,489
45	Availability of hepatitis C diagnostics and therapeutics in European and Eurasia countries. Antiviral Research, 2018, 150, 9-14.	4.1	17
46	Coinfections between Persistent Parasitic Neglected Tropical Diseases and Viral Infections among Prisoners from Sub-Saharan Africa and Latin America. Journal of Tropical Medicine, 2018, 2018, 1-10.	1.7	6
47	Expert Opinion on the Management of Renal Manifestations of Chronic HCV Infection. Antiviral Therapy, 2018, 23, 57-67.	1.0	4
48	The comprehensive outcomes of hepatitis C virus infection: A multiâ€faceted chronic disease. Journal of Viral Hepatitis, 2018, 25, 6-14.	2.0	23
49	Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?. PLoS ONE, 2018, 13, e0209374.	2.5	12
50	Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of Hepatology, 2018, 69, 718-735.	3.7	474
51	Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016â€“2030. Journal of Hepatology, 2018, 69, 896-904.	3.7	1,157
52	Collagen proportionate area correlates to hepatic venous pressure gradient in non-abstinent cirrhotic patients with alcoholic liver disease. World Journal of Hepatology, 2018, 10, 73-81.	2.0	14
53	A buyersâ€™ club to improve access to hepatitis C treatment for vulnerable populations. Swiss Medical Weekly, 2018, 148, w14649.	1.6	6
54	Hepatitis B prevalence, risk factors, infection awareness and disease knowledge among inmates: a cross-sectional study in Switzerland's largest pre-trial prison. Journal of Global Health, 2018, 8, 020407.	2.7	4

#	Article	IF	Citations
55	Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Gastroenterology and Hepatology, 2017, 2, 161-176.	8.1	1,619
56	A systematic review and metaâ€analysis of <scp>HCV</scp> clearance. Liver International, 2017, 37, 1431-1445.	3.9	37
57	Cardiovascular Manifestations of Hepatitis C Virus. Clinics in Liver Disease, 2017, 21, 465-473.	2.1	23
58	Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. Journal of Advanced Research, 2017, 8, 149-159.	9.5	39
59	Nucleic acid polymers: much-needed hope for hepatitis D?. The Lancet Gastroenterology and Hepatology, 2017, 2, 841-842.	8.1	4
60	Hepatic protein tyrosine phosphatase receptor gamma links obesity-induced inflammation to insulin resistance. Nature Communications, 2017, 8, 1820.	12.8	40
61	The impact of hepatitis C virus outside the liver: Evidence from Asia. Liver International, 2017, 37, 159-172.	3.9	38
62	Extrahepatic manifestations in hepatitis C virus infection. Journal of Advanced Research, 2017, 8, 85-87.	9.5	8
63	BRIP1coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease. Oncotarget, 2017, 8, 62842-62857.	1.8	7
64	Access to hepatitis C treatment for patients in drug substitution programmes: the fight is far from over. Swiss Medical Weekly, 2017, 147, w14570.	1.6	3
65	Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease. World Journal of Gastroenterology, 2016, 22, 3735.	3.3	11
66	Effect of Quercetin on Hepatitis C Virus Life Cycle: From Viral to Host Targets. Scientific Reports, 2016, 6, 31777.	3.3	81
67	The hepatitis delta virus: Replication and pathogenesis. Journal of Hepatology, 2016, 64, S102-S116.	3.7	212
68	Management of HCV Infection. , 2016, , 61-78.		0
69	A significant effect of the killer cell immunoglobulinâ€like receptor ligand human leucocyte antigenâ€C on fibrosis progression in chronic C hepatitis with or without liver transplantation. Liver International, 2016, 36, 1331-1339.	3.9	4
70	Nonalcoholic Steatohepatitis Is Associated With Increased Mortality in Obese Patients Undergoing Bariatric Surgery. Clinical Gastroenterology and Hepatology, 2016, 14, 1619-1628.	4.4	47
71	Dysregulation of distal cholesterol biosynthesis in association with relapse and advanced disease in CHC genotype 2 and 3 treated with sofosbuvir and ribavirin. Journal of Hepatology, 2016, 64, 29-36.	3.7	30
72	Ribavirin restores IFNÎ± responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut, 2016, 65, 672-682.	12.1	16

#	Article	IF	Citations
73	Hepatitis C Virus Increases Occludin Expression via the Upregulation of Adipose Differentiation-Related Protein. PLoS ONE, 2016, 11, e0146000.	2.5	8
74	Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations. PLoS ONE, 2016, 11, e0155464.	2.5	9
75	Drug Pricing Evolution in Hepatitis C. PLoS ONE, 2016, 11, e0157098.	2.5	16
76	Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PLoS ONE, 2015, 10, e0125214.	2.5	25
77	Are statins a remedy for all seasons?. Journal of Hepatology, 2015, 62, 8-10.	3.7	3
78	Extrahepatic Morbidity and Mortality of Chronic Hepatitis C. Gastroenterology, 2015, 149, 1345-1360.	1.3	306
79	Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection. Reviews on Recent Clinical Trials, 2015, 9, 204-209.	0.8	17
80	Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland. Swiss Medical Weekly, 2015, 145, w14221.	1.6	8
81	Epidemiology of hepatitis C in Europe. Digestive and Liver Disease, 2014, 46, S158-S164.	0.9	70
82	Hepatitis D Virus Coinfection and Superinfection. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a021550-a021550.	6.2	94
83	Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. Journal of Hepatology, 2014, 61, S69-S78.	3.7	139
84	Reduced IFNÎ»4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes. Nature Communications, 2014, 5, 5699.	12.8	117
85	Does telaprevir possess a direct antidiabetic effect?. Liver International, 2014, 34, 967-969.	3.9	7
86	Origin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3e. Journal of General Virology, 2014, 95, 1677-1688.	2.9	34
87	HCV causes systemic disorders that can be cured. Nature Reviews Gastroenterology and Hepatology, 2014, 11, 77-78.	17.8	18
88	Curbing hepatitis C virus spread in Egypt. The Lancet Global Health, 2014, 2, e495-e496.	6.3	3
89	The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis C. Clinics in Liver Disease, 2014, 18, 147-156.	2.1	23
90	Is genotype 3 of the hepatitis C virus the new villain?. Hepatology, 2014, 59, 2403-2412.	7.3	116

#	Article	IF	Citations
91	HCV 3a Core Protein Increases Lipid Droplet Cholesteryl Ester Content via a Mechanism Dependent on Sphingolipid Biosynthesis. PLoS ONE, 2014, 9, e115309.	2.5	23
92	Role of seipin in lipid droplet morphology and hepatitis C virus life cycle. Journal of General Virology, 2013, 94, 2208-2214.	2.9	9
93	Intrahepatic <scp>mRNA</scp> levels of SOCS1 and SOCS3 are associated with cirrhosis but do not predict virological response to therapy in chronic hepatitis C. Liver International, 2013, 33, 94-103.	3.9	5
94	Homeostasis model assessment of insulin resistance does not seem to predict response to telaprevir in chronic hepatitis C in the REALIZE trial. Hepatology, 2013, 58, 1897-1906.	7.3	21
95	PTEN protein phosphatase activity regulates hepatitis C virus secretion through modulation of cholesterol metabolism. Journal of Hepatology, 2013, 59, 420-426.	3.7	37
96	Nonalcoholic Fatty Liver Disease in Lean Individuals in the United States. Medicine (United States), 2012, 91, 319-327.	1.0	441
97	The interaction of metabolic factors with HCV infection: Does it matter?. Journal of Hepatology, 2012, 56, S56-S65.	3.7	152
98	HCV Infection and Metabolic Syndrome: Which Is the Chicken and Which Is the Egg?. Gastroenterology, 2012, 142, 1288-1292.	1.3	31
99	Genome-Wide Association Study Identifies Variants Associated With Progression of Liver Fibrosis From HCV Infection. Gastroenterology, 2012, 143, 1244-1252.e12.	1.3	142
100	Post-load insulin resistance does not predict virological response to treatment of chronic hepatitis C patients without the metabolic syndrome. Digestive and Liver Disease, 2012, 44, 419-425.	0.9	10
101	IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes. Hepatology, 2012, 55, 384-394.	7.3	138
102	Mechanisms of hepatitis C virus-related insulin resistance. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 358-363.	1.5	21
103	Current understanding of insulin resistance in hepatitis C. Expert Review of Gastroenterology and Hepatology, 2011, 5, 503-516.	3.0	44
104	Viral genotype-specific role of PNPLA3 , PPARG , MTTP, and IL28B in hepatitis C virus-associated steatosis. Journal of Hepatology, 2011, 55, 529-535.	3.7	98
105	Hepatitis D virus: an update. Liver International, 2011, 31, 7-21.	3.9	108
106	The homeostasis model assessment of the insulin resistance score is not predictive of a sustained virological response in chronic hepatitis C patients. Liver International, 2011, 31, 66-74.	3.9	32
107	The global health burden of hepatitis C virus infection. Liver International, 2011, 31, 1-3.	3.9	121
108	A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International, 2011, 31, 30-60.	3.9	333

#	Article	IF	Citations
109	Effects of hepatitis C virus on suppressor of cytokine signaling mRNA levels: Comparison between different genotypes and core protein sequence analysis. Journal of Medical Virology, 2011, 83, 1005-1015.	5.0	21
110	Down-regulation of phosphatase and tensin homolog by hepatitis C virus core 3a in hepatocytes triggers the formation of large lipid droplets. Hepatology, 2011, 54, 38-49.	7.3	66
111	Adverse effects of drugs in the treatment of viral hepatitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 183-192.	2.4	47
112	Cause-effect relationship between the hepatitis C virus and insulin resistance at the time of direct antiviral therapy. Gut, 2010, 59, 1590-1591.	12.1	2
113	Hepatitis C Virus-Induced Steatosis: An Overview. Digestive Diseases, 2010, 28, 294-299.	1.9	35
114	Abnormalities of lipid metabolism in hepatitis C virus infection. Gut, 2010, 59, 1279-1287.	12.1	157
115	Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study. Gastroenterology, 2010, 138, 1338-1345.e7.	1.3	1,056
116	The hepatitis C virus core protein indirectly induces alpha-smooth muscle actin expression in hepatic stellate cells via interleukin-8. Journal of Hepatology, 2010, 52, 635-643.	3.7	54
117	Hepatitis C Virus Infection: Molecular Pathways to Steatosis, Insulin Resistance and Oxidative Stress. Viruses, 2009, 1, 126-143.	3.3	40
118	Peroxisome Proliferator-Activated Receptors and Hepatitis C Virus-Induced Insulin Resistance. PPAR Research, 2009, 2009, 1-6.	2.4	13
119	Hepatitis delta virus inhibits alpha interferon signaling. Hepatology, 2009, 49, 398-406.	7.3	88
120	Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data. Liver International, 2009, 29, 26-37.	3.9	142
121	Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. Journal of Hepatology, 2009, 51, 655-666.	3.7	247
122	Hepatitis C virus and type 2 diabetes. World Journal of Gastroenterology, 2009, 15, 1537.	3.3	140
123	Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C. Liver International, 2008, 28, 370-376.	3.9	31
124	Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes. Hepatology, 2008, 48, 799-807.	7.3	74
125	Steatosis in chronic hepatitis C: friend or foe?. Liver International, 2008, 28, 294-296.	3.9	2
126	Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. Journal of Hepatology, 2008, 48, 28-34.	3.7	177

#	Article	IF	Citations
127	Pioglitazone in chronic hepatitis C not responding to pegylated interferon-Î± and ribavirin. Journal of Hepatology, 2008, 49, 295-298.	3.7	76
128	Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. Journal of Hepatology, 2008, 49, 429-440.	3.7	91
129	Cohort Profile: The Swiss Hepatitis C Cohort Study (SCCS). International Journal of Epidemiology, 2007, 36, 731-737.	1.9	63
130	Hepatitis C Virus Induces Proteolytic Cleavage of Sterol Regulatory Element Binding Proteins and Stimulates Their Phosphorylation via Oxidative Stress. Journal of Virology, 2007, 81, 8122-8130.	3.4	240
131	HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project). Gastroenterology, 2007, 133, 1132-1143.	1.3	57
132	The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype-specific mechanisms. Hepatology, 2007, 45, 1164-1171.	7.3	214
133	Relationship Between Steatosis, Inflammation, and Fibrosis in Chronic Hepatitis C: A Meta-Analysis of Individual Patient Data. Gastroenterology, 2006, 130, 1636-1642.	1.3	517
134	Insulin resistance and HCV: Will new knowledge modify clinical management?. Journal of Hepatology, 2006, 45, 514-519.	3.7	52
135	Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7408-7413.	7.1	651
136	Mechanisms and significance of liver steatosis in hepatitis C virus infection. World Journal of Gastroenterology, 2006, 12, 6756.	3.3	136
137	An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation. Journal of Hepatology, 2005, 42, 744-751.	3.7	155
138	International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C. Journal of Hepatology, 2005, 43, 250-257.	3.7	143
139	Nonradioisotopic <I>In Situ</I> Hybridization for HDV RNA. , 2004, 95, 95-98.		0
140	Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. Transplant International, 2004, 17, 169-176.	1.6	9
141	Antigenic relevance of F protein in chronic hepatitis C virus infection. Hepatology, 2004, 40, 900-909.	7.3	20
142	Oral lichen planus pathogenesis: A role for the HCV-specific cellular immune response. Hepatology, 2002, 36, 1446-1452.	7.3	53
143	Lack ofin vivo blockade of Fas- and TNFR1-mediated hepatocyte apoptosis by the hepatitis C virus. Journal of Pathology, 2002, 197, 617-623.	4.5	17
144	Expression of liver steatosis in hepatitis C virus infection and pattern of response to Î±-interferon. Journal of Hepatology, 2001, 35, 307.	3.7	63

#	Article	IF	Citations
145	Acute valproate-associated microvesicular steatosis: could the [13C]methionine breath test be useful to assess liver mitochondrial function?. Digestive Diseases and Sciences, 2001, 46, 2758-2761.	2.3	18
146	Detection of the negative-strand hepatitis C virus RNA in tissues: implications for pathogenesis. Antiviral Research, 2001, 52, 161-171.	4.1	15
147	Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. Journal of Medical Virology, 2000, 60, 21-27.	5.0	56
148	Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. Journal of Hepatology, 2000, 33, 106-115.	3.7	532
149	Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. Journal of Medical Virology, 2000, 60, 21.	5.0	3
150	Detection of genomic- and minus-strand of hepatitis C virus RNA in the liver of chronic hepatitis C patients by strand-specific semiquantitative reversetranscriptase polymerase chain reaction. Hepatology, 1999, 29, 536-542.	7.3	61
151	Lack of hepatitis C virus replication intermediate RNA in diseased skin tissue of chronic hepatitis C patients. , 1999, 59, 277-280.		23
152	Primary Hepatic Diffuse Large B-Cell Lymphoma in a Patient with Chronic Hepatitis C. American Journal of Surgical Pathology, 1999, 23, 1124.	3.7	18
153	Does the hepatitis C virus replicate in cells of the hematopoietic lineage?. Hepatology, 1998, 28, 261-264.	7.3	18
154	IgM anti-hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Journal of Medical Virology, 1998, 56, 224-229.	5.0	23
155	Detection of intrahepatic hepatitis C virus replication by strand-specific semi-quntitative RT-PCR: preliminary application to the liver transplantation model. Journal of Hepatology, 1998, 29, 1-11.	3.7	54
156	IgM antiâ€hepatitis C virus core antibodies as marker of recurrent hepatitis C after liver transplantation. Journal of Medical Virology, 1998, 56, 224-229.	5.0	3
157	Lack of monomeric IgM anti-hepatitis C virus (HCV) core antibodies in patients with chronic HCV infection. Journal of Virological Methods, 1996, 60, 179-182.	2.1	6
158	Evidence for replication of hepatitis delta virus RNA in hepatocyte nuclei after in vivo infection. Virology, 1988, 167, 274-278.	2.4	67
159	Chronic HDV (hepatitis delta virus) hepatitis. Journal of Hepatology, 1988, 6, 8-14.	3.7	66